Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01396148 · ClinicalTrials.gov registry record · Phase 2
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01396148 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 6 participants.
The verdict
NCT01396148, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Children and young adults with gastrointestinal stromal tumors (GIST) will be treated with sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be studied in these patients. In addition, tumor responses and overall survival will be assessed.
Interventions
- DRUG sunitinib malate
- DRUG sunitinib malate dose escalation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-06 |
| Est. Completion | 2017-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01396148
The ClinicalTrials.gov registry entry for NCT01396148 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sunitinib malate is the first listed.
NCT01396148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01396148 about?
NCT01396148 is a clinical study titled "A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor". Children and young adults with gastrointestinal stromal tumors (GIST) will be treated with sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be studied in these patients. In addition, tumor responses and overall survival will be assessed.
What is the current status of trial NCT01396148?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2012-06. Estimated completion is 2017-08.
What interventions are being tested in trial NCT01396148?
The interventions under investigation include: sunitinib malate (DRUG), sunitinib malate dose escalation (DRUG).
Who is sponsoring clinical trial NCT01396148?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.